Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.43 |
| ▸ | ITK | Q08881 | 5/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | PLK4 | O00444 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PRKCG | P05129 | 1/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | FES | P07332 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | ROS1 | P08922 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.39 |
| ▸ | FER | P16591 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359421 | 0.86 | MET (0.48) | METITKJAK2DYRK1APLK4 | |
| SCHEMBL1358491 | 0.86 | MET (0.48) | METITKJAK2DYRK1APLK4 | |
| SCHEMBL1357809 | 0.86 | MET (0.48) | METITKJAK2DYRK1APLK4 | |
| SCHEMBL1357872 | 0.86 | MET (0.40) | METITKJAK2DYRK1APLK4 | |
| SCHEMBL1359646 | 0.85 | MET (0.39) | METITKJAK2DYRK1APLK4 | |
| SCHEMBL1358648 | 0.84 | ITK (0.46) | ITKJAK2DYRK1APLK4AURKA | |
| SCHEMBL1360157 | 0.84 | MET (0.41) | METITKJAK2DYRK1APLK4 | |
| SCHEMBL415757 | 0.81 | BRAF (0.40) | ITKJAK2DYRK1APLK4AURKA | |
| SCHEMBL27910785 | 0.80 | MET (0.40) | METITKJAK2DYRK1APLK4 | |
| SCHEMBL1358010 | 0.80 | MET (0.40) | METITKJAK2DYRK1APLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569314-B1 | FUSED BICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20140088114-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals ,LLC | 2014-03-27 | — | — | US | disclosed |
| US-20140088114-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals ,LLC | 2014-03-27 | — | — | US | disclosed |
| US-20140088114-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals ,LLC | 2014-03-27 | — | — | US | disclosed |
| US-8592448-B2 | Substituted pyrrolo[2,3-b]-pyridines and -pyrazines | OSI Pharmaceuticals, LLC (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-8445510-B2 | Fused bicyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2569314-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2012158658-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2011-11-17 | — | — | US | disclosed |
| WO-2011143645-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110224191-A1 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines | OSI Pharmaceuticals, LLC | 2011-09-15 | — | — | US | disclosed |
| EP-2356116-A1 | SUBSTITUTED PYRROLOÝ2,3-B¨-PYRIDINES AND-PYRAZINES | OSI Pharmaceuticals, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010059771-A1 | SUBSTITUTED PYRROLO[2,3-B]-PYRIDINES AND-PYRAZINES | OSI PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | ALK, RET, MET | MET 3/4885ITK 315/4885JAK2 21/4885 |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | ALK, RET, MET | MET 3/4885ITK 315/4885JAK2 21/4885 |
| US-20110224191-A1 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines | MET, RET, KRAS | MET 1/4885ITK 2186/4885JAK2 5/4885 |
| US-20140088114-A1 | FUSED BICYCLIC KINASE INHIBITORS | IGF1R, MET, RET | MET 2/4885ITK 260/4885JAK2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.